Latest news with #Eisai
Yahoo
23-05-2025
- Business
- Yahoo
Eisai to Present E7386, Co-created by PRISM BioLab and Eisai, at the ASCO (American Society of Clinical Oncology) Annual Meeting
Abstract Released for E7386, Co-Developed Through Collaborative Research Between Eisai and PRISM TOKYO, May 22, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced that the analysis of a combination study of E7386(*1), created through collaboration research with Eisai Co., Ltd. ("Eisai"), and Lenvatinib mesylate ("lenvatinib") (*2) will be presented by Eisai at the American Society of Clinical Oncology (ASCO) Congress 2025, held in Chicago, USA from May 30 to June 3, 2025. The abstract of the study has been released today. To determine the optimal dose of E7386 in combination with Lenvatinib in the open-label Phase Ib study (NCT04008797(*3)), expansion cohort of advanced endometrial cancer patients progressed following platinum-based chemotherapy and anti-PD-(L)1 immunotherapy have been implemented by Eisai and the enrollment of 30 patients was completed. By data cutoff (Oct 22, 2024), with 9 patients remaining on treatment, 30% (9 patients) showed the confirmed response (decrease of tumor size > 30%) for an overall response rate of 30.0%. Furthermore, among patients without prior Lenvatinib treatment, the overall response rate was 42.9%. Completing the enrollment of dose expansion cohort (n=30), the results confirmed promising preliminary antitumor activity of E7386 + Lenvatinib with a manageable safety profile. For the subsequent dose-optimization part for E7386 + LEN in advanced endometrial cancer, enrollment of patients had been initiated (NCT04008797). (*1) E7386 E7386 is an orally available small molecule CBP/ β-catenin inhibitor that inhibits protein-protein interactions between the transcription factor CBP and β-catenin, and regulates the Wnt signaling. E7386 achieved clinical POC (Proof of concept) in October 2021 and following clinical studies are ongoing including phase I for solid tumors as monotherapy, Phase Ib for solid tumors in combination with tyrosine kinase inhibitor Lenvatinib, Phase Ib/II for solid tumors in combination with pembrolizumab, the anti-PD-1 antibody from Merck & Co., Inc., Rahway, NJ, USA. (*2) Lenvatinib Lenvatinib is a multi-kinase inhibitor, discovered by Eisai and being co-developed and co-commercialized under a collaboration agreement with Merck & Co., Inc., Rahway, NJ, USA, which inhibits vascular endothelial growth factor receptors (VEGFRs),VEGFR1, VEGR2, VEGFR3 and fibroblast growth factor receptors (FGFRs), FGFR1, FGFR2, FGFR3, FGFR4, and other receptor tyrosine kinases, PDGFR-alpha, KIT, RET. Lenvatinib have been approved for thyroid cancer, hepatocellular carcinoma, thymic caner and renal cell carcinoma (in combination with Everolimus or pembrolizumab, the anti-PD-1 antibody from Merck & Co., Inc., Rahway, NJ, USA.). Lenvatinib is also approved for endometrium cancer in combination with pembrolizumab (*3) NCT04008797 NCT04008797 is an open-label Phase Ib study of E7386 in combination with other anticancer drug, Lenvatinib for the patients with solid tumors. The study has been implemented by Eisai in Japan, Korea, Taiwan region, US, and France determine the safety and the recommended phase 2 dose (RP2D) and also to see the pharmacokinetics and efficacy of E7386 + Lenvatinib. Enrolment of each cohort of hepatic, colon, endometrial cancers are ongoing. About PRISM BioLab PRISM BioLab is a discovery and development biotechnology company utilizing proprietary PepMetics® technology to discover orally available small molecule inhibitors of protein-protein interaction (PPI) targets and transform lives of patients suffering from cancer, autoimmune, fibrosis and other diseases. PepMetics® are a unique class of small molecules that mimic three-dimensional structures of alpha-helix and beta-turn, the peptide structures commonly found in intracellular PPI interphases and receptor-ligand interactions. By combining proprietary chemistry, know-how around PPI targets and AI-supported design, PepMetics® technology can deliver inhibitors of challenging PPI targets. The technology holds promise to expand the field of drug discovery by turning previously undruggable PPIs into targets readily druggable with small molecules and by generating oral small molecule alternatives for injectable biologics. PRISM BioLab is collaborating on new PPI targets with global and Japanese pharmaceutical companies. PepMetics® targeting CBP/beta-catenin PPIs licensed to Eisai Co., Ltd. and Ohara Pharmaceuticals Co., Ltd. are in clinical development for cancer and liver disease, respectively. View original content to download multimedia: SOURCE PRISM BioLab Co., Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Japan Today
19-05-2025
- Japan Today
Tamaryokucha: Japan's rare green tea you've probably never heard of
By Elizabeth Sok 'Do you have any shin-cha?' the older gentleman to my left asked in a thick Hakata dialect. I had just bought some first harvest tea myself from my favorite tea shop and was waiting for it to be wrapped. 'Yes, we just received a shipment of chiran-cha (tea from the Chiran region of Kagoshima Prefecture) yesterday. Would you like to sample a cup?' the cashier replied. She was already preparing to scoop some fresh tea leaves into a yokode kyusu (single-sided handle Japanese teapot). Mid-scoop, the man interjected, 'What about tamaryokucha?' 'I'm sorry, we just sold the last one. But we have…' It was too late. With no more than a grunt, he brushed by the couple behind him on his way elsewhere in search of his drink of choice. In hushed tones, one of them said to the other, 'What's tamaryokucha?' How green tea took root in Japan This is all that remains of Saga Prefecture's Ryosenji, an important site in the history of tea in Japan. Image: Krkrkrme/CC BY-SA 4.0 Trying not to draw attention to myself as I eavesdropped, I picked up a small pamphlet on display. As well as offering steeping instructions, it also gave a quick history of tea in Japan. Tea was introduced to Japan via China at the turn of the ninth century. But, cultivation was very limited and drinking tea remained primarily among Buddhist monks and some members of the imperial court. Ultimately, interest died out before long. Fast forward to the late 12th century and the pilgrimages of Eisai, a Zen Buddhist monk. He too returned to Japan with tea, this time in the form of tea plant seeds. On the borderlands of present-day Saga and Fukuoka Prefectures on Mount Sefuri, Eisai planted several seeds on the grounds of Ryosenji. Kyoto and Uji were next to cultivate tea, but this time in the first large-scale plantations. Over the centuries, tea production spread to a few other areas, namely Shizuoka and Kagoshima. Sen no Rikyu began to formalize the Japanese tea ceremony in the 16th century and matcha became the drink of choice among the samurai class. Sencha was later developed in the 18th century. Over 100 years later, tea farmers began to produce wakoucha (Japanese black tea) which gained a following overseas and accounted for nearly two-thirds of all tea exports in 1955. These days, you're likely to find some other well-known teas, including houjicha (roasted green tea), genmaicha (roasted brown rice tea) or even gyokuro, a premium-grade green tea. What is 'tamaryokucha'? Steep yourself in this rare green tea Tea preparation in Song Dynasty China before the invention of pan-firing tea leaves. Image: LIu Songnian/Public domain In the end, the couple was won over by the chiran-cha sample and bought a bag as well as some matcha-flavored ice cream for the road. Meanwhile, another store clerk placed a sold-out sign where tamaryokucha would normally be found. In case you didn't notice, tamaryokucha isn't usually on lists of the greatest hits of Japanese teas. And despite Japan's reputation as a consumer paradise, you probably won't find it among the many offerings at most tea shops in Japan. Here's why: tamaryokucha makes up only about three percent of the country's total tea production with the vast majority originating from Saga's Ureshino area. There are two types of tamaryokucha: kama-iri-sei (pan-fired) and mushi-sei (steamed). Out of the two, the steamed variety is by far the most common. Kama-iri-sei tamaryokucha Rather than using steam to heat dry tea leaves, kama-iri-sei tamaryokucha depends on a kama (an iron pot or pan) to roast them in a process developed during China's Ming Dynasty (1368-1644). Next, they are rubbed before drying. The pan-fired variety is marked by its more nutty and earthy notes at the heart of a fuller tasting tea. These days, less than one percent of teas in Japan are pan-fired. Mushi-sei tamaryokucha The origins of mushi-sei tamaryokucha go back to the 1920s. Looking for new markets to export its tea, Japan turned to the Soviet Union which had been buying Chinese pan-fired tea. Creating a steam-powered process to increase productivity, but with similarly curly and tasty results, Japan began to export mushi-sei tamaryokucha in high volume to the Soviet Union. Shizuoka quickly became the nation's leading producer, pumping out almost 8,000 tons between 1934 and 1941 and dwarfing Kyushu's collective output. To make mushi-sei tamaryokucha, you first steam dry tea leaves at a high temperature while removing condensation as it appears. This process is repeated until, finally, the leaves are left to dry into their characteristically curly shape. Sencha and other green teas are also steamed, but mushi-sei tamaryokucha is steamed for a longer duration. The result is relatively less astringency and rich flavor that can handle being steeped in 80 to 90-degree water for about a minute. Just because it's a relatively rare tea doesn't mean tamaryokucha is impossible to find. Nor does it mean you'll have to pay a premium price. Where to buy tamaryokucha in Japan or online Nagasaki Prefecture's Sonogi region is home to one of 2024's best Japanese teas. Image: ゆう/Pixta Most big supermarket chains don't stock it on the shelves, but you can find some tamaryokucha sourced from Ureshino and Miyazaki Prefecture in Aeon and OK's online inventories. Aeon Kyushu Online carries tamaryokucha from Nagasaki's Sonogi region. But, while these may be the most convenient options, they can't beat the quality of tamaryokucha sold from dedicated tea shops and cultivators. Founded in 1936, Haraguchien is my go-to for tamaryokucha sourced from Ureshino. With only three stores (all located in Fukuoka) that spotlight teas mainly from Ureshino, Yame (Fukuoka) and Chiran (Kagoshima), it's a local small business with deep roots in southern Japanese tea culture. If you want one of the best tamaryokucha around, look no further than Ikeda Cha-en who earned Platinum prizes at the prestigious 2024 Nihoncha Awards. Located in Sonogi, they've made the underdog tea region proud after being selected out of a field of more than 500 teas of all types. Curious to try pan-fired tamaryokucha? Although Ikeda Noen is a small-scale production, they've been in operation since 1907 and produce my favorite version, complete with a refreshing taste and unmistakable roasted aroma. Tamaryokucha in modern Japanese sweets and treats While the number of tamaryokucha-infused treats on the market is far from the near-monopoly that matcha holds, a few retailers offer alternate ways to savor its rich flavor. Fraglace, a company specializing in organic craft ice cream, offers tamaryokucha-infused scoops along with others featuring tea as key ingredients. Over in Shimane Prefecture, a tea shop named Chadonya sells roll cakes baked with tamaryokucha. Start your day with a cup of tamaryokucha Ureshino may not be a household name, but it's the largest producer of tamaryokucha in the country and the origin of my breakfast tea. Image: kattyan/Pixta 'I apologize for the wait. Here's your tamaryokucha,' the tea store clerk said as she handed me my bag. I thanked her and headed home. Before breakfast the next day, I made myself a pot, steeped in 75 degree water for about 50 seconds for that full-bodied flavor with a touch of sweetness. As the morning wore on, I re-steeped it once or twice more for a little longer, each cup getting a little mellower, revealing faint nutty notes. Some people need to start their day with a cup of coffee. While I'm not one of those people, I get it — just like I understand the plight of the older gentleman. Like me, I hope he finally found his rare cup in a sea of green. © Japan Today
Bloomberg
19-05-2025
- Health
- Bloomberg
Alzheimer's Drugs Arrive in Taiwan to a Host of Questions
Hi, it's Amber in Hong Kong. Across the strait in Taiwan, breakthrough Alzheimer's drugs are finally becoming available but experts are cautious about using them. Before I explain … The first therapies shown to slow Alzheimer's disease – Kisunla from Eli Lilly and Leqembi from Biogen and Eisai – are set to become available in Taiwan in June. They're the first new treatment option for the condition in 20 years.
Bloomberg
19-05-2025
- Health
- Bloomberg
Eisai Shares Rise as New Alzheimer's Test Seen Helping Sales
Shares of Japanese drugmaker Eisai Co. gained after US regulators approved the first blood test to help diagnose Alzheimer's disease, fueling expectations of an uptick in demand for drugs used to treat the illness. Eisai's stock rose as much as 3.5% on Monday in Tokyo, the most in a month. The test, made by a unit of Japan's H.U. Group Holdings Inc., was cleared for people 55 and older who exhibit signs and symptoms of Alzheimer's, the US Food and Drug Administration said in a statement Friday. H.U. Group shares jumped as much as 8.6%, the most in a year.
Time of India
17-05-2025
- Health
- Time of India
US FDA clears first blood test for Alzheimer's detection
Bengaluru: The U.S. Food and Drug Administration has cleared Fujirebio Diagnostics ' blood test to diagnose Alzheimer's disease, the regulator said on Friday, making the device the first of its kind to detect the brain-wasting condition. Blood tests could speed up diagnosis of the disease and make it easier for more people to access its treatments such as Biogen and Eisai's Leqembi and Eli Lilly's Kisunla, since traditional tests are often costly or uncomfortable. Fujirebio's test, branded as Lumipulse, checks for two proteins in the blood and uses their ratio to help detect signs of amyloid beta plaque, considered a hallmark of the disease, in the brain. Other options to detect Alzheimer's include procedures such as a spinal tap, which requires an invasive puncture to collect spinal fluid, or an expensive PET brain scan that may not be reimbursed by health insurers. "Street expectations for both therapies (Leqembi and Kisunla) are modest" with a slow ramp over the next few years, given the lack of access to neurologists, said Citi analyst Geoffrey Meacham. "An approved blood-based diagnostic is a positive in a disease area that has been starved of game-changing innovation." Biogen has been doubling down on Leqembi but it has failed to live up to lofty expectations due to concerns over cost, efficacy and side effects. In the first quarter, Leqembi brought $96 million in sales, while Lilly recorded $21.5 million in Kisunla sales. Lumipulse and C2N Diagnostics' PrecivityAD2 were the top two performers when compared with four other commercial blood tests for Alzheimer's, according to a study led by researchers at Washington University School of Medicine. Biogen has partnered with Fujirebio, and Eisai is collaborating with C2N to clinically advance and commercialize blood tests that can detect Alzheimer's risk.
